STAAR Surgical Co stock (US8577001096): shares consolidate after Q1-driven jump on Nasdaq

STAAR Surgical Co shares on Nasdaq are stabilizing after a sharp Q1-related move in May, keeping the United States-based eye-care group in focus for investors tracking medical technology names.

STAAR Surgical Co shares on the Nasdaq in the United States are trading in a narrower range again after a sharp Q1-related move in mid-May put the eye-care stock back on the radar of medical technology investors.

Trading data for Nasdaq-listed STAAR Surgical Co under the ticker STAA indicate the stock most recently changing hands around the high-20s in USD terms, with a one-day move of a few percent and a modest rebound over the past week, while the market capitalization stands in the hundreds of millions of dollars according to recent price and market cap snapshots as of late May 2026 on platforms such as TradingView and Financhill.

As of: 01/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: STAA
• Sector/industry: Ophthalmic medical technology
• Headquarters/country: Lake Forest, United States
• Core markets: Vision-correction procedures in North America, Europe and Asia
• Key revenue drivers: Implantable collamer lenses and related vision-correction products
• Home exchange/listing venue: Nasdaq (STAA)
• Trading currency: USD

STAAR Surgical Co: core business model

STAAR Surgical Co develops and manufactures implantable lenses and other ophthalmic devices that generate most of its revenue from surgeons and clinics performing refractive vision-correction procedures worldwide.

What banks and research houses say about STAAR Surgical Co

Recent commentary from research-focused news providers in the United States indicates that STAAR Surgical Co has returned to investors screens after its latest quarterly report, with at least one detailed note highlighted by StreetInsider on 05/20/2026 describing the company as signaling standalone strength as a potential overhang from Alcon fades following the strong Q1 performance.

While the StreetInsider coverage on 05/20/2026 does not publish a full model with public rating language and a numerical 12-month price target, it reflects that at least one U.S.-based research house is reassessing STAAR Surgical Co after the company reported its latest quarterly figures and as competitive dynamics in ophthalmic implants evolve.

Conclusion

STAAR Surgical Co shares on Nasdaq are stabilizing after a Q1-driven re-rating move in May, leaving the United States-based ophthalmic group trading in the high-20s USD range with a market value in the mid-hundreds of millions of dollars.

With StreetInsider highlighting that at least one research house now views STAAR Surgical Co as showing standalone strength as the Alcon overhang fades after strong Q1 metrics, analyst and investor attention is likely to stay focused on execution in core implantable lens markets and on how the company navigates competition in premium vision-correction procedures.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.